The deal carries a 40% premium and has strong insider support (28% already committed). Key risks are regulatory, FDA decisions on zidesamtinib (Sept 18) and neladalkib (Nov 27), and HSR clearance. The stock should trade near the offer price minus a small spread for timing and regulatory risk. Monitor for any competing bids given the termination fee structure.
How the stock moved after the report
BULLISH VIEWSTOCK ABOVE ENTRY AT T+20- T+0 · Jun 9 $123.25entry
- T+1 · 5mo ago +0.08%α +1.66% · $123.35
- T+5 · 5mo ago +0.08%α −2.33% · $123.35
- T+20 · 4mo ago +0.42%α −1.02% · $123.77
- T+60 · due 3mo ago Pending
Price Chart
REPLAYWatch the reaction play outHow similar events traded
Executive Summary
GSK plc has agreed to acquire Nuvalent for $124.00 per share in cash, representing a total equity value of $10.6 billion. The transaction includes two late-stage ROS1 and ALK inhibitors (zidesamtinib and neladalkib) under FDA review with 2026 target action dates, plus a phase I HER2 inhibitor. Stockholders representing ~28% of Class A shares have signed tender and support agreements to tender their shares. The deal is expected to close in Q3 2026, subject to regulatory approval and a majority-of-shares tender condition.
Key Financial Metrics
Key Facts
- GSK to acquire Nuvalent for $124.00 per share in cash, aggregate equity value of $10.6 billion
- Purchase price represents a 40% premium to last closing price and a 26% premium to 30-day VWAP
- Two late-stage assets (zidesamtinib for ROS1+ NSCLC, neladalkib for ALK+ NSCLC) under FDA review with PDUFA dates of Sept 18, 2026 and Nov 27, 2026
- Third asset NVL-330 (HER2 inhibitor) in phase I for HER2-altered NSCLC
- Supporting stockholders (Deerfield affiliates, directors, officers) owning ~28% of Class A shares have agreed to tender
- Termination fee of $350,475,000 payable by Nuvalent under certain circumstances
- Transaction expected to close in Q3 2026; GSK expects low single-digit percentage dilution to core EPS in FY 2026-2028, accretion to core EPS in 2029
- GSK to fund primarily from new and existing debt plus cash; no financing condition
Financial Impact
$10.6 billion aggregate equity value; $124.00 per share cash consideration; net of cash acquired GSK's investment estimated at $9.4 billion
Risk Factors
- FDA non-approval or delayed approval of zidesamtinib or neladalkib could delay or jeopardize the deal
- HSR antitrust review could extend timeline or impose conditions
- Shareholder litigation could create delays or additional costs
- GSK's ability to fund the transaction is not subject to a financing condition, but debt markets could shift
Market Snapshot
Investment Themes
Documents Analyzed
This report is based on 6 SEC documents filed with EDGAR.
| Document | Accession Number |
|---|---|
| 8-K Filing (Primary) | 0001193125-26-262950 |
| Document: d137459dex101.htm | 0001193125-26-262950 |
| Document: d137459dex991.htm | 0001193125-26-262950 |
| Document: d137459d8k.htm | 0001193125-26-262950 |
| Document: 0001193125-26-262950-index-headers.html | 0001193125-26-262950 |
| Document: 0001193125-26-262950.txt | 0001193125-26-262950 |
Track record
18 reports on NUVL
3 of 6 bullish or bearish reports moved the stock their way by T+20. Best: +21.01% at T+60 after the Apr 7, 2026 report. 3 of 7 went positive at some point.
Filters
- Jul 27, 202616w ago 15-12G Neutral 3/10 No price data
- Jul 15, 202617w ago 25-NSE Neutral 3/10 Entry $123.96 No price data
- Jul 15, 202617w ago 8-K Bullish 5/10 Entry $123.96 No price data
- Jul 8, 202618w ago Insider Cluster Neutral 3/10 Entry $123.80 No price data
- Jul 6, 202619w ago Insider Cluster Neutral 3/10 Entry $123.72 No price data
- Jun 11, 202622w ago Insider Cluster Neutral 2/10 Entry $123.25 to $123.90 ▲ +0.53% −1.25% vs SPY
- Jun 10, 202622w ago Insider Cluster Neutral 3/10 Entry $123.45 to $123.83 ▲ +0.31% −1.58% vs SPY
- Jun 9, 202622w ago 8-K Bullish 8/10 Viewing Entry $123.25 to $123.77 ▲ +0.42% −1.02% vs SPY
- May 7, 202627w ago 8-K Neutral 4/10 Entry $102.40 to $90.18 ▼ −11.93% −15.07% vs SPY
- Apr 29, 202628w ago Insider Cluster Neutral 2/10 Entry $99.10 to $107.38 ▲ +8.36% +2.90% vs SPY
US Market Status
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers